--- title: "Cytek Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 44.14 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285658128.md" datetime: "2026-05-08T03:30:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285658128.md) - [en](https://longbridge.com/en/news/285658128.md) - [zh-HK](https://longbridge.com/zh-HK/news/285658128.md) --- # Cytek Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 44.14 M Revenue: As of FY2026 Q1, the actual value is USD 44.14 M, missing the estimate of USD 44.3 M. EPS: As of FY2026 Q1, the actual value is USD -0.15. EBIT: As of FY2026 Q1, the actual value is USD -18.99 M. #### Segment Revenue - Product revenue for the first quarter of 2026 was $28,779 thousand, compared to $28,110 thousand in the first quarter of 2025 . - Service revenue for the first quarter of 2026 was $15.4 million, a 15% increase compared to the first quarter of 2025 . Service revenue was $15,356 thousand for Q1 2026, up from $13,347 thousand in Q1 2025 . - Total recurring revenue, comprising service and reagent revenues, reached $18.4 million in the first quarter of 2026 . - On a trailing-12-month basis, recurring revenue accounted for 35% of total revenue, an increase from 31% as of the first quarter of 2025 . #### Gross Profit and Margin - GAAP gross profit was $21.3 million for the first quarter of 2026, a 5% increase compared to the first quarter of 2025 . GAAP gross profit was $21,254 thousand for Q1 2026, compared to $20,157 thousand for Q1 2025 . - GAAP gross profit margin was 48% in the first quarter of 2026, down from 49% in the first quarter of 2025 . - Adjusted gross profit margin was 51% in the first quarter of 2026, compared to 52% in the first quarter of 2025 . #### Operating Expenses - Total operating expenses were $39.7 million for the first quarter of 2026, a 13% increase compared to the first quarter of 2025 . Total operating expenses were $39,717 thousand for Q1 2026, compared to $35,132 thousand for Q1 2025 . - Research and development expenses decreased by 1% to $9.6 million in the first quarter of 2026, from $9,725 thousand in Q1 2025 to $9,604 thousand in Q1 2026 . - Sales and marketing expenses decreased by 7% to $11.6 million in the first quarter of 2026, from $12,509 thousand in Q1 2025 to $11,646 thousand in Q1 2026 . - General and administrative expenses increased by 43% to $18.5 million in the first quarter of 2026, from $12,898 thousand in Q1 2025 to $18,467 thousand in Q1 2026, primarily due to litigation-related expenses, outside consulting expenses, and bad debt reserves . #### Profitability - Loss from operations was - $18.5 million in the first quarter of 2026, compared to - $15.0 million in the first quarter of 2025 . - Net loss in the first quarter of 2026 was - $18.9 million, compared to a net loss of - $11.4 million in the first quarter of 2025 . - Adjusted EBITDA loss in the first quarter of 2026 was - $9.1 million, compared to an adjusted EBITDA loss of - $3.3 million in the first quarter of 2025 . #### Cash and Marketable Securities - Cash and marketable securities totaled $262.2 million as of March 31, 2026, an increase of $0.7 million from $261.5 million as of December 31, 2025 . - Cash and cash equivalents were $65,665 thousand as of March 31, 2026, compared to $90,853 thousand as of December 31, 2025 . - Marketable securities were $196,560 thousand as of March 31, 2026, compared to $170,676 thousand as of December 31, 2025 . #### Operational Metrics (Installed Base) - Cytek Biosciences, Inc. expanded its total installed base to 3,789 instruments, adding 125 units in the first quarter of 2026 . #### 2026 Outlook - Cytek Biosciences, Inc. reaffirms its 2026 revenue guidance to be in the range of $205 million to $212 million . This represents a projected growth of 2% to 5% over full year 2025, assuming no change from current currency exchange rates . ### Related Stocks - [CTKB.US](https://longbridge.com/en/quote/CTKB.US.md) ## Related News & Research - [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | CLRB Stock News](https://longbridge.com/en/news/286406208.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [OceanPal Inc. Announces 2026 Annual General Meeting of Shareholders to be Held on June 16, 2026 | SVRN Stock News](https://longbridge.com/en/news/286308382.md) - [Kyivstar Delivers Strong Start to 2026 with Diverse, Profitable Growth | KYIV Stock News](https://longbridge.com/en/news/286193954.md)